METHODS A systematic review of evidence-based literature was performed using Medline and Cochrane databases. Studies reviewed include randomized controlled.

Slides:



Advertisements
Similar presentations
Human Trials Gold standard: Controlled, double-blind; versus greater potential of whole food diet Vitamins/minerals/etc. for learning and behavior (Controlled,
Advertisements

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
Mortality benefit from reduction in sodium consumption 1 Hypertension affects one-third of the US population, of which less than half have their blood.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Valsartan Antihypertensive Long-Term Use Evaluation Results
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Vitamins - what is the evidence? Rohan Subasinghe.
METHODS Systematic review of evidenced-based medicine.Systematic review of evidenced-based medicine. A review of the literature was done using a combined.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Dietetic Guidelines for Secondary Prevention of Cardiovascular Disease Alison Mead Chief Dietitian On behalf of UK Heart Health and Thoracic Dietitian’s.
1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Randomized, double-blind, multicenter, controlled trial.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Cardiovascular Disease in Women Module I: Epidemiology.
Omega-3 Fatty Acids: An Untapped Resource for Improving Health
ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients Daan Kromhout, MPH PhD for the Alpha Omega Trial Group.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Vitamin D Supplementation Emily Sedlock PA-S Lock Haven University of PA Physician Assistant Program Emily Sedlock PA-S Lock Haven University of PA Physician.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Systematic Review of Dietary Supplement Efficacy and Safety Paul M. Coates, Ph.D. Office of Dietary Supplements National Institutes of Health Department.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
 2010 Wellsource, Inc. All rights reserved. Polyunsaturated Fats and CHD Harvard Study 2010.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Circulating Long-Chain ω-3 Fatty Acids and Incidence of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study Funded by: National Institutes.
Placing the Risks into Perspective ACSM, Risk of Acute Events  DOES EXERCISE INCREASE THE RISK OF ACUTE CARDIOVASCULAR EVENTS?  Vigorous physical.
Manny Noakes Research Director CSIRO FOOD AND NUTRITION Omega-3 Nutrition- Fish versus Supplements.
Evaluating the Medical Evidence ​ A TOOLKIT FOR THE INTERPRETING THE EFFECTIVENESS OF INTERVENTIONS Niteesh Choudhy, M.D., Ph.D.
N-3fatty acids in cardiovascular disease DR.AMINI.
The Role of Secondary Versus Tertiary Prevention in Decreasing the Incidence of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus Lindsay.
Methodological Issues in Systematic Review - Formulating Questions - Joseph Lau, MD Tufts Medical Center EPC AHRQ Annual Meeting September 10, 2008.
4S: Scandinavian Simvastatin Survival Study
Food and cardiovascular heart disease Pedro Marques-Vidal IUMSP Lausanne, Switzerland.
Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Alarm Sensors: Evaluating the Effectiveness in Reducing Elderly Inpatient Falls Jenna Barnwell, RN Jessica Cantrell, RN Sabrina George, RN Whitney Holman,
SECONDARY PREVENTION IN HEART DISEASE CATHY QUICK AUBURN UNIVERSITY/AUBURN MONTGOMERY EBP III.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fish Intake, Contaminants, and Human Health: Evaluating.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Journal of the American College of Cardiology Vol. 61, No. 4, 2013 Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
The ALERT Trial.
The Rise and Fall of Hormone Replacement Therapy
From Inuit to Implementation: Omega-3 Fatty Acids Come of Age
A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.
United States Preventive Services Task Force: Recommendations for ABPM
AIM HIGH Niacin plus Statin to prevent vascular events
RAAS Blockade: Focus on ACEI
A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.
The Chemical Differences Between EPA and DHA.
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Figure 2 Absolute difference in seasonal peak
Nat. Rev. Cardiol. doi: /nrcardio
LRC-CPPT and MRFIT Content Points:
Daan Kromhout, et al. NEJM epub August 29, 2010
From Inuit to Implementation: Omega-3 Fatty Acids Come of Age
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Omega-3 fatty acid supplements during pregnancy
Presentation transcript:

METHODS A systematic review of evidence-based literature was performed using Medline and Cochrane databases. Studies reviewed include randomized controlled trials, meta-analyses and systematic reviews of randomized controlled trials, and cohort studies. Studies reviewed included the following criteria: ► Randomized trials comparing dietary or supplemental intake of omega-3 fatty acids with a control diet or placebo ►Trials reporting cardiac endpoints such as fatal or nonfatal MI and overall mortality, ►Trials following patients with established coronary heart disease for at least 6 months. CONCLUSIONS The majority of the literature shows a decrease in myocardial reinfarction in patients already diagnosed with coronary heart disease with the incorporation of fatty fish intake or supplementation with long chain omega-3 fatty acids. The evidence appears especially strong for a beneficial effect of omega-3 fatty acids in preventing sudden cardiac death due to fatal cardiac arrhythmias. However, the quality of studies conducted to this point is suboptimal and more studies are needed to confirm and further define the health benefits of omega-3 fatty acids for preventing subsequent cardiovascular events. At this time there is insufficient evidence to make a recommendation to include omega-3 fatty acids for prevention of myocardial reinfarction in patients with existing coronary heart disease. Omega-3 Fatty Acids Compared to Placebo in Secondary Prevention of Myocardial Reinfarction Abigail M. Moos MS Ed, PA-S and Sue M. Nyberg MHS, PA-C Department of Physician Assistant Wichita State University, Wichita, KSINTRODUCTION During the last 35 years, omega-3 polyunsaturated fatty acids have emerged as a topic of scientific scrutiny and public interest. In the 1970’s, epidemiological studies of Greenland Eskimos linked their diet, high in whale, seal, and fish rich in omega-3 polyunsaturated fatty acids, to a low incidence of cardiovascular mortality. Research shows promising evidence indicating that moderate doses of omega-3 polyunsaturated fatty acids not only reduce the risk of cardiovascular disease, but decrease mortality due to myocardial reinfarction, sudden death, and overall mortality in patients with established coronary heart disease. This study aims to investigate the protective properties of long chain omega-3 fatty acids, particularly DHA and EPA. This study will focus on both dietary and supplemental interventions in populations with established coronary heart disease and the prevalence of myocardial reinfarction, sudden death, and overall mortality. RESULTS Ten studies made up the literature review including five Level 1 randomized controlled trials, two Level 1 meta- Analyses of randomized controlled trials, and three Level 2 prospective cohort studies. Research shows supplementation with omega-3 fatty acids in patients with existing coronary heart disease decreases the incidence of all cause mortality, fatal myocardial reinfarction, and sudden death due to fatal cardiac arrhythmias. ►Studies show incorporating fatty fish or omega-3 fatty acids supplementation into the diet reduces all cause mortality between 15-30%. ► Studies show supplementation of omega-3 fatty acids decrease myocardial reinfarction by 20-25%. ► Studies report an % decrease in sudden cardiac death due to fatal cardiac arrhythmias with incorporation of omega-3 fatty acids. DISCUSSION Research shows supplementation with omega-3 fatty acids in patients with existing coronary heart disease decreases the incidence of all cause mortality, fatal myocardial reinfarction, and sudden death due to fatal cardiac arrhythmias. However, the quality of research is plagued with limitations including: ►Implementing multiple dietary changes ►Varying amounts of EPA and DHA ►Utilizing dietary recall to estimate omega-3 intake Gaps in the Literature requiring further investigation include: ►RCTs performed on US populations ►RCTs including women and minorities ►Exploration of the most beneficial dose of omega-3 fatty acids ►Determination of the optimal ratio of EPA to DHA Studies showing a decrease in 4 outcomes due to omega-3 fatty acid supplementation in patients diagnosed with CHD Non-fatal MI Fatal MI SCD All-Cause M/M Nilsen et al Singh et al ♥ ♥ ♥ Burr et al ♥ ♥ ♥ Marchioli et al ♥ ♥ ♥ ♥ De Lorgeril et al ♥♥ ♥ Bucher et al ♥ ♥ ♥ Yzebe et al ♥ ♥ Morris et al ♥ Hu et al ♥ Daviglus et al ♥ ♥ *SCD – Sudden cardiac death M/M – morbidity and mortality MI –myocardial infarction